
Please try another search
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Name | Age | Since | Title |
---|---|---|---|
Alfred J. Novak | 77 | 2022 | Independent Director |
Luca Rastelli | 57 | - | Member of Scientific Advisory Board |
Tiago Reis Marques | 47 | 2020 | CEO & Director |
Simon Dumesnil | 47 | 2021 | Independent Director |
Daniel R. Weinberger | - | 2022 | Member of Scientific Advisory Board |
Lawrence Steinman | 77 | 2020 | Co-Founder, MD & Executive Chairman |
Emer Leahy | 58 | 2021 | Independent Director |
Rebecca Brown | - | 2024 | Member of Scientific Advisory Board |
James Lee | - | 2025 | Scientific Advisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review